“Growth was broad based across the company,” said Hasit Joshipura, MD, GSK Pharma–ceuticals.
“Mass markets grew well. Vaccines continued the growth momentum by growing ahead of the market. Mass Specialty and Specialty, both showed market competitive growth.”
Net sales rose 16% to Rs.656.69 crore against Rs.566 crore for the year-ago period.
The company said its board has recommended a dividend of Rs.50 per equity share for the year.
“If approved by the shareholders, the dividend will absorb Rs.424 crore,” said the company.
Shares closed at Rs.2,103, up 0.5% on the BSE.